LOGIN
Darexaban vs placebo for prevention of VTE in Asian patients receiving TKA or THA
May 2014
Darexaban vs placebo for prevention of VTE in Asian patients receiving TKA or THA
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Darexaban for the Prevention of Venous Thromboembolism in Asian Patients Undergoing Orthopedic Surgery: Results From 2 Randomized, Placebo-Controlled, Double-Blind Studies
Clin Appl Thromb Hemost. 2014 Mar;20(2):199-211Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
996 Asian patients undergoing TKA (1 study) and THA (second study) surgery were randomly assigned into 1 of 4 groups to determine if darexaban effectively and safely reduced the occurrence of venous thromboembolism (VTE) when compared to an oral placebo or subcutaneous enoxaparin. The four possible treatment methods were: a 15 or 30 mg oral dose of darexaban, a 20 mg subcutaneous injection of enox...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.